Phase 2 study of PDS0101 in combination with KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy.

Trial Profile

Phase 2 study of PDS0101 in combination with KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy.

Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top